Critical Appraisal of Reimbursement List in Bosnia and Herzegovina.
作者信息
Mujkic Sabina, Marinkovic Valentina
机构信息
Regulatory Affairs Department, Alvogen Pharma d.o.o. Sarajevo, Bosnia and Herzegovina.
Department of Social Pharmacy and Pharmaceutical Legislation, Faculty of Pharmacy, University of Belgrade Belgrade, Serbia.
出版信息
Front Pharmacol. 2017 Mar 17;8:129. doi: 10.3389/fphar.2017.00129. eCollection 2017.
Abstract
摘要
相似文献
1
Critical Appraisal of Reimbursement List in Bosnia and Herzegovina.波斯尼亚和黑塞哥维那报销清单的批判性评估。
Front Pharmacol. 2017 Mar 17;8:129. doi: 10.3389/fphar.2017.00129. eCollection 2017.
2
HEALTH TECHNOLOGY ASSESSMENT IN CENTRAL-EASTERN AND SOUTH EUROPE COUNTRIES: BOSNIA AND HERZEGOVINA.中东欧和东南欧国家的卫生技术评估：波斯尼亚和黑塞哥维那。
Int J Technol Assess Health Care. 2017 Jan;33(3):390-395. doi: 10.1017/S0266462317000058. Epub 2017 Apr 24.
3
4
Budget Impact of Introducing Linagliptin into Bosnia and Herzegovina Health Insurance Drug Reimbursement List in 2016-2018.2016 - 2018年将利格列汀纳入波斯尼亚和黑塞哥维那医疗保险药品报销清单的预算影响
Mater Sociomed. 2017 Sep;29(3):176-181. doi: 10.5455/msm.2017.29.176-181.
5
Analysis of evidence supporting the Federation of Bosnia and Herzegovina reimbursement medicines lists: role of the WHO Essential Medicines List, Cochrane systematic reviews and technology assessment reports.支持波斯尼亚和黑塞哥维那联邦报销药品清单的证据分析：世界卫生组织基本药物清单、考克兰系统评价及技术评估报告的作用。
Eur J Clin Pharmacol. 2015 Jul;71(7):825-33. doi: 10.1007/s00228-015-1861-8. Epub 2015 May 10.
6
Being Immigrant in their Own Country: Experiences of Bosnians Immigrants in Contact with Health Care System in Bosnia and Herzegovina.在自己国家成为移民：波斯尼亚移民在波斯尼亚和黑塞哥维那与医疗保健系统接触的经历。
Mater Sociomed. 2015 Feb;27(1):4-9. doi: 10.5455/msm.2014.27.4-9. Epub 2015 Feb 21.
7
Perinatal mortality in the Federation of Bosnia and Herzegovina.波斯尼亚和黑塞哥维那联邦的围产期死亡率。
J Perinat Med. 2001;29(3):247-9. doi: 10.1515/JPM.2001.035.
8
Development of an essential drugs list for Bosnia and Herzegovina.波斯尼亚和黑塞哥维那基本药物清单的制定。
J R Soc Med. 1997 Jun;90(6):331-3. doi: 10.1177/014107689709000610.
9
Development of emergency medicine as academic and distinct clinical discipline in Bosnia & Herzegovina.波斯尼亚和黑塞哥维那急诊医学作为一门学术性且独特的临床学科的发展。
Med Arh. 2011;65(1):46-51. doi: 10.5455/medarh.2011.65.46-51.
10
Diabetology Care During COVID-19 Lockdown in Bosnia and Herzegovina - Diabetologists and Patients Perspective.波斯尼亚和黑塞哥维那新冠疫情封锁期间的糖尿病护理——糖尿病专家和患者视角
Mater Sociomed. 2020 Sep;32(3):183-186. doi: 10.5455/msm.2020.32.183-186.
引用本文的文献
1
Population Perspectives on Impact of the COVID-19 Pandemic on Essential Health Services-Behavioral Insights from the Federation of Bosnia and Herzegovina.波斯尼亚和黑塞哥维那联邦关于 COVID-19 大流行对基本卫生服务影响的民众观点——行为洞察
Behav Sci (Basel). 2022 Dec 3;12(12):495. doi: 10.3390/bs12120495.
2
Physician Practice and Knowledge on Diabetes Management During Ramadan in Bosnia and Herzegovina.波斯尼亚和黑塞哥维那斋月期间医生对糖尿病管理的实践与知识
Mater Sociomed. 2020 Mar;32(1):57-61. doi: 10.5455/msm.2020.32.57-61.
3
Pharmacoeconomic Analysis of Antiepileptic Reimbursement for Neuropathic Pain in Bosnia and Herzegovina - Budget Impact Analysis of Pregabalin.波斯尼亚和黑塞哥维那抗癫痫药物治疗神经性疼痛的药物经济学分析——普瑞巴林的预算影响分析
Mater Sociomed. 2018 Jun;30(2):89-94. doi: 10.5455/msm.2018.30.89-94.
4
Medicine Availability and Prescribing Policy for Non-Communicable Diseases in the Western Balkan Countries.西巴尔干国家非传染性疾病的药品供应与处方政策
Front Public Health. 2017 Nov 8;5:295. doi: 10.3389/fpubh.2017.00295. eCollection 2017.
本文引用的文献
1
Abstracts from the 3rd International PPRI Conference 2015: Pharmaceutical Pricing and Reimbursement Policies: Challenges Beyond the Financial Crisis.2015年第三届国际药品定价与报销政策会议摘要：金融危机之外的挑战
J Pharm Policy Pract. 2015 Oct 5;8 Suppl 1(Suppl 1):E1-P29. doi: 10.1186/2052-3211-8-S1-E1.
2
Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.1990 - 2015年79种行为、环境与职业及代谢风险或风险群组的全球、区域和国家比较风险评估：全球疾病负担研究2015的系统分析
Lancet. 2016 Oct 8;388(10053):1659-1724. doi: 10.1016/S0140-6736(16)31679-8.
3
Evolving Health Expenditure Landscape of the BRICS Nations and Projections to 2025.金砖国家不断演变的卫生支出格局及到2025年的预测
Health Econ. 2017 Jul;26(7):844-852. doi: 10.1002/hec.3406. Epub 2016 Sep 29.
4
Health Economics at the Crossroads of Centuries - From the Past to the Future.世纪之交的健康经济学——从过去到未来。
Front Public Health. 2016 Jun 9;4:115. doi: 10.3389/fpubh.2016.00115. eCollection 2016.
5
The New and Old Europe: East-West Split in Pharmaceutical Spending.新旧欧洲：制药支出的东西方分化
Front Pharmacol. 2016 Feb 9;7:18. doi: 10.3389/fphar.2016.00018. eCollection 2016.
6
Life expectancy and health expenditure evolution in Eastern Europe-DiD and DEA analysis.东欧的预期寿命与医疗支出演变——双重差分法与数据包络分析
Expert Rev Pharmacoecon Outcomes Res. 2016 Aug;16(4):537-46. doi: 10.1586/14737167.2016.1125293. Epub 2015 Dec 17.
7
Budget Impact of Publicly Reimbursed Prescription Medicines in the Republic of Srpska.塞族共和国公共报销处方药的预算影响
Front Public Health. 2015 Sep 10;3:213. doi: 10.3389/fpubh.2015.00213. eCollection 2015.
8
Resource allocation strategies in Southeastern European health policy.东南欧卫生政策中的资源分配策略。
Eur J Health Econ. 2013 Apr;14(2):153-9. doi: 10.1007/s10198-012-0439-y.
9
Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member States.将克罗地亚的药品定价和报销政策与欧盟成员国进行比较。
Croat Med J. 2011 Apr 15;52(2):183-97. doi: 10.3325/cmj.2011.52.183.
10
Reimbursement of pharmaceuticals: reference pricing versus health technology assessment.药品报销：参考定价与卫生技术评估。
Eur J Health Econ. 2011 Jun;12(3):263-71. doi: 10.1007/s10198-010-0274-y. Epub 2010 Aug 28.
Zotero 插件